{
    "Clinical Trial ID": "NCT01964924",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Trametinib, Akt Inhibitor GSK2141795)",
        "  PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.",
        "  PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  Akt Inhibitor GSK2141795: Given PO",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Trametinib: Given PO"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients must have histologically or cytologically confirmed metastatic invasive breast cancer that is negative for the estrogen receptor (ER), progesterone receptor (PR) and HER2 by institutional guidelines",
        "  Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])",
        "  Patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer",
        "  Patients must consent to both a pretreatment and a post-treatment mandatory research biopsy prior to enrolling on trial, and therefore, must have tissue (excluding bone or brain) that is amenable to biopsy",
        "  Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
        "  Life expectancy of greater than 3 months",
        "  Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels",
        "  All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade =< 1 (except alopecia) at the time of enrollment",
        "  Absolute neutrophil count >= 1,500/mcL",
        "  Platelets >= 75,000/mcL",
        "  Total bilirubin =< 1.5 \u00d7 institutional upper limit of normal",
        "  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 \u00d7 institutional upper limit of normal",
        "  Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)",
        "  Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min",
        "  Patients must have controlled blood pressure with a systolic blood pressure < 140 mmHg and diastolic < 90 mmHg; anti-hypertensive medications are permitted",
        "  Patients must be at least 4 weeks from last radiation dose; patients must be at least 4 weeks from last chemotherapy, targeted therapy, or biologic therapy (exception allowed for a 2 week washout for patients who were on chemotherapy at less than a standard of care dose, as long as all other eligibility criteria are met); patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications",
        "  Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib monotherapy or in combination with GSK2141795 administration",
        "  Ability to understand and the willingness to sign a written informed consent document",
        "Exclusion Criteria:",
        "  History of another malignancy",
        "  Exception: patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible",
        "  History of interstitial lung disease or pneumonitis",
        "  History of type I diabetes mellitus; if a patient has type II diabetes, they must have a hemoglobin (hemoglobin A1C) =< 8%; patients with a screening fasting glucose > 120 mg/dL will be excluded",
        "  Uncontrolled hypothyroidism; patients must have a normal thyroid-stimulating hormone (TSH) per institutional standards at baseline",
        "  Patients who are receiving any other investigational agents",
        "  Individuals with symptomatic or progressive brain metastases are ineligible; subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks after completion of local therapy; any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment",
        "  History of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795",
        "  Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:",
        "  Other anti-cancer therapy while on study treatment (megestrol if used as an appetite stimulant is allowed)",
        "  The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, yohimbe, saw palmetto, or ginseng)",
        "  Patients receiving strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible",
        "  History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes; visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mm Hg",
        "  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
        "  Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795",
        "  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib",
        "  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
        "  Time frame: 6 months",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Trametinib, Akt Inhibitor GSK2141795)",
        "  Arm/Group Description: PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.",
        "  PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  Akt Inhibitor GSK2141795: Given PO",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Trametinib: Given PO",
        "  Overall Number of Participants Analyzed: 37",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  2   5.4%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 30/37 (81.08%)",
        "  Anemia 1/37 (2.70%)",
        "  Leukocytosis 1/37 (2.70%)",
        "  Cardiac arrest 1/37 (2.70%)",
        "  Vertigo 1/37 (2.70%)",
        "  Diarrhea 0/37 (0.00%)",
        "  Dysphagia 1/37 (2.70%)",
        "  Enterocolitis 0/37 (0.00%)",
        "  Vomiting 0/37 (0.00%)",
        "  Death NOS 1/37 (2.70%)",
        "  Edema face 1/37 (2.70%)",
        "  Edema limbs 1/37 (2.70%)",
        "  Fever 1/37 (2.70%)"
    ]
}